Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.64
(1.19%)
USD 0.64
(1.19%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.1 Million USD | 87.62% |
| 2022 | -57.33 Million USD | 56.16% |
| 2021 | -130.79 Million USD | -46.56% |
| 2020 | -89.24 Million USD | -147.75% |
| 2019 | -36.02 Million USD | 68.05% |
| 2018 | -112.72 Million USD | -349.33% |
| 2017 | -25.08 Million USD | -38.49% |
| 2016 | -18.11 Million USD | 73.93% |
| 2015 | -69.48 Million USD | -1052.27% |
| 2014 | -6.03 Million USD | 40.8% |
| 2013 | -10.18 Million USD | 53.01% |
| 2012 | -21.67 Million USD | -29.3% |
| 2011 | -16.76 Million USD | -55.47% |
| 2010 | -10.78 Million USD | 49.03% |
| 2009 | -21.15 Million USD | -9.02% |
| 2008 | -19.4 Million USD | -58.12% |
| 2007 | -12.27 Million USD | 3.36% |
| 2006 | -12.7 Million USD | 31.37% |
| 2005 | -18.5 Million USD | -114.55% |
| 2004 | -8.62 Million USD | 12.01% |
| 2003 | -9.8 Million USD | 44.42% |
| 2002 | -17.63 Million USD | -139.69% |
| 2001 | -7.35 Million USD | 27.5% |
| 2000 | -10.15 Million USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 1.31 Million USD | 105.35% |
| 2024 Q1 | -24.51 Million USD | -245.3% |
| 2023 Q2 | -30.45 Million USD | 24.87% |
| 2023 FY | -7.1 Million USD | 87.62% |
| 2023 Q4 | -7.1 Million USD | 67.04% |
| 2023 Q1 | -40.54 Million USD | 29.29% |
| 2023 Q3 | -21.53 Million USD | 29.28% |
| 2022 FY | -57.33 Million USD | 56.16% |
| 2022 Q2 | -76.17 Million USD | 1.64% |
| 2022 Q1 | -77.44 Million USD | 40.79% |
| 2022 Q3 | -54.86 Million USD | 27.98% |
| 2022 Q4 | -57.33 Million USD | -4.5% |
| 2021 Q2 | -132.55 Million USD | -56.84% |
| 2021 Q1 | -84.51 Million USD | 5.3% |
| 2021 FY | -130.79 Million USD | -46.56% |
| 2021 Q4 | -130.79 Million USD | 7.13% |
| 2021 Q3 | -140.83 Million USD | -6.25% |
| 2020 Q1 | -45.55 Million USD | -26.45% |
| 2020 Q3 | -221.13 Million USD | 48.36% |
| 2020 Q4 | -89.24 Million USD | 59.64% |
| 2020 FY | -89.24 Million USD | -147.75% |
| 2020 Q2 | -428.2 Million USD | -840.06% |
| 2019 Q4 | -36.02 Million USD | 51.11% |
| 2019 Q3 | -73.68 Million USD | 42.29% |
| 2019 Q2 | -127.67 Million USD | -88.67% |
| 2019 Q1 | -67.66 Million USD | 39.97% |
| 2019 FY | -36.02 Million USD | 68.05% |
| 2018 Q4 | -112.72 Million USD | -811.31% |
| 2018 FY | -112.72 Million USD | -349.33% |
| 2018 Q3 | -12.37 Million USD | 62.77% |
| 2018 Q2 | -33.22 Million USD | -531.79% |
| 2018 Q1 | -5.25 Million USD | 79.04% |
| 2017 Q3 | -26.02 Million USD | 60.54% |
| 2017 Q2 | -65.95 Million USD | -353.02% |
| 2017 Q4 | -25.08 Million USD | 3.6% |
| 2017 FY | -25.08 Million USD | -38.49% |
| 2017 Q1 | -14.55 Million USD | 19.64% |
| 2016 Q2 | -12.7 Million USD | 61.25% |
| 2016 FY | -18.11 Million USD | 73.93% |
| 2016 Q4 | -18.11 Million USD | 29.59% |
| 2016 Q3 | -25.73 Million USD | -102.47% |
| 2016 Q1 | -32.79 Million USD | 52.8% |
| 2015 FY | -69.48 Million USD | -1052.27% |
| 2015 Q1 | -25.25 Million USD | -318.84% |
| 2015 Q2 | -10.76 Million USD | 57.36% |
| 2015 Q4 | -69.48 Million USD | -102.65% |
| 2015 Q3 | -34.28 Million USD | -218.42% |
| 2014 Q1 | -126.82 Million USD | -1145.07% |
| 2014 Q2 | -99.27 Million USD | 21.73% |
| 2014 FY | -6.03 Million USD | 40.8% |
| 2014 Q3 | -11.2 Million USD | 88.71% |
| 2014 Q4 | -6.03 Million USD | 46.18% |
| 2013 Q1 | -12.17 Million USD | 43.83% |
| 2013 Q4 | -10.18 Million USD | 87.32% |
| 2013 FY | -10.18 Million USD | 53.01% |
| 2013 Q3 | -80.3 Million USD | -566.35% |
| 2013 Q2 | -12.05 Million USD | 1.03% |
| 2012 FY | -21.67 Million USD | -29.3% |
| 2012 Q4 | -21.67 Million USD | -57.96% |
| 2012 Q3 | -13.72 Million USD | 25.72% |
| 2012 Q2 | -18.47 Million USD | 24.56% |
| 2012 Q1 | -24.49 Million USD | -46.07% |
| 2011 FY | -16.76 Million USD | -55.47% |
| 2011 Q4 | -16.76 Million USD | 22.62% |
| 2011 Q3 | -21.66 Million USD | -157.3% |
| 2011 Q2 | -8.42 Million USD | -22.42% |
| 2011 Q1 | -6.87 Million USD | 36.21% |
| 2010 Q4 | -10.78 Million USD | -19.09% |
| 2010 FY | -10.78 Million USD | 49.03% |
| 2010 Q1 | -12.2 Million USD | 42.32% |
| 2010 Q2 | -12.78 Million USD | -4.79% |
| 2010 Q3 | -9.05 Million USD | 29.2% |
| 2009 Q3 | -14.09 Million USD | 4.57% |
| 2009 FY | -21.15 Million USD | -9.02% |
| 2009 Q4 | -21.15 Million USD | -50.07% |
| 2009 Q2 | -14.77 Million USD | -0.89% |
| 2009 Q1 | -14.64 Million USD | 24.56% |
| 2008 Q2 | -8.65 Million USD | 12.91% |
| 2008 Q4 | -19.4 Million USD | -121.99% |
| 2008 FY | -19.4 Million USD | -58.12% |
| 2008 Q1 | -9.94 Million USD | 19.01% |
| 2008 Q3 | -8.74 Million USD | -0.98% |
| 2007 Q4 | -12.27 Million USD | 27.34% |
| 2007 Q1 | -11.03 Million USD | 13.16% |
| 2007 Q3 | -16.89 Million USD | -74.67% |
| 2007 Q2 | -9.67 Million USD | 12.31% |
| 2007 FY | -12.27 Million USD | 3.36% |
| 2006 Q1 | -13.39 Million USD | 27.61% |
| 2006 Q3 | -16.11 Million USD | 44.11% |
| 2006 Q2 | -28.83 Million USD | -115.24% |
| 2006 Q4 | -12.7 Million USD | 21.19% |
| 2006 FY | -12.7 Million USD | 31.37% |
| 2005 FY | -18.5 Million USD | -114.55% |
| 2005 Q3 | -10.52 Million USD | -36.57% |
| 2005 Q2 | -7.7 Million USD | -1.15% |
| 2005 Q1 | -7.62 Million USD | 11.66% |
| 2005 Q4 | -18.5 Million USD | -75.81% |
| 2004 Q2 | -7.78 Million USD | 18.16% |
| 2004 Q1 | -9.51 Million USD | 2.98% |
| 2004 FY | -8.62 Million USD | 12.01% |
| 2004 Q3 | -6.62 Million USD | 14.94% |
| 2004 Q4 | -8.62 Million USD | -30.28% |
| 2003 Q3 | -12.1 Million USD | -23.47% |
| 2003 FY | -9.8 Million USD | 44.42% |
| 2003 Q2 | -9.8 Million USD | 22.12% |
| 2003 Q4 | -9.8 Million USD | 19.01% |
| 2003 Q1 | -12.58 Million USD | 28.64% |
| 2002 Q2 | -32.82 Million USD | -4.29% |
| 2002 Q1 | -31.47 Million USD | -327.69% |
| 2002 FY | -17.63 Million USD | -139.69% |
| 2002 Q3 | -15.34 Million USD | 53.24% |
| 2002 Q4 | -17.63 Million USD | -14.93% |
| 2001 FY | -7.35 Million USD | 27.5% |
| 2001 Q4 | -7.35 Million USD | 65.3% |
| 2001 Q3 | -21.2 Million USD | -39.86% |
| 2001 Q2 | -15.16 Million USD | 5.54% |
| 2001 Q1 | -16.05 Million USD | -58.12% |
| 2000 Q1 | 2.02 Million USD | 0.0% |
| 2000 FY | -10.15 Million USD | 0.0% |
| 2000 Q2 | -39.58 Million USD | -2052.94% |
| 2000 Q4 | -10.15 Million USD | -11.0% |
| 2000 Q3 | -9.14 Million USD | 76.9% |
| 1999 FY | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 93.104% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 77.256% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 103.585% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 122.268% |
| bluebird bio, Inc. | 108.57 Million USD | 106.539% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 21.251% |
| Imunon, Inc. | -4.69 Million USD | -51.087% |
| Editas Medicine, Inc. | -87.11 Million USD | 91.85% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.055% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 100.338% |
| Myriad Genetics, Inc. | 88.1 Million USD | 108.059% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 104.005% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 78.823% |
| Verastem, Inc. | -37.27 Million USD | 80.954% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 100.086% |
| Waters Corporation | 1.96 Billion USD | 100.362% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.026% |
| Biogen Inc. | 6.28 Billion USD | 100.113% |
| Nektar Therapeutics | 210.24 Million USD | 103.377% |
| Perrigo Company plc | 3.32 Billion USD | 100.214% |
| Dynavax Technologies Corporation | 106.63 Million USD | 106.658% |
| Illumina, Inc. | 1.21 Billion USD | 100.585% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 201.893% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 93.766% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 104.894% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 198.789% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 101.875% |
| Evolus, Inc. | 63.7 Million USD | 111.145% |
| Adicet Bio, Inc. | -142 Million USD | 95.0% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 80.709% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 73.801% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 101.548% |
| FibroGen, Inc. | 56.76 Million USD | 112.507% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 100.62% |
| OPKO Health, Inc. | 230.68 Million USD | 103.078% |
| Homology Medicines, Inc. | 18.43 Million USD | 138.51% |
| Geron Corporation | 14.76 Million USD | 148.1% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 100.448% |
| Exelixis, Inc. | -73.05 Million USD | 90.281% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 86.914% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 95.299% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 93.627% |
| Zoetis Inc. | 4.76 Billion USD | 100.149% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 96.447% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 29.501% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.926% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 51.276% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.673% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.733% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 94.756% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.514% |
| Blueprint Medicines Corporation | 702.83 Million USD | 101.01% |
| Insmed Incorporated | 721.62 Million USD | 100.984% |
| TG Therapeutics, Inc. | 17.86 Million USD | 139.749% |
| Incyte Corporation | -3.17 Billion USD | 99.776% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 100.927% |